Fig. 1

First etanercept treatment course, therapy survival and reasons for discontinuation and follow-up of patients who discontinued etanercept after achieving an inactive disease (single categories (ineffectiveness, adverse events, other reasons, unknown) do not add up to the rate of other reasons than inactive disease by the possibility of multiple responses)